PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2005 September; 6(3): E421–E428.
Published online 2005 October 22. doi:  10.1208/pt060352
PMCID: PMC2750386

Supercritical assisted atomization: A novel technology for microparticles preparation of an asthma-controlling drug

Abstract

The objective of this study was to produce microparticles of a new asthma-controlling drug by supercritical assisted atomization (SAA), proposed as an alternative to conventional jet-milling process. SAA is based on the solubilization of supercritical carbon dioxide in a liquid solution containing the drug; the ternary mixture is then sprayed through a nozzle, and microparticles are formed as a consequence of the enhanced atomization. SAA process parameters studied were precipitator temperature, nozzle diameter, and drug concentration in the liquid solution. Their influence was evaluated on morphology and size of precipitated particles. Spherical particles with mean particle size ranging from 1 to 3 μm of the new anti-asthma drug were produced by SAA. The mass median aerodynamic diameter (MMAD) of the SAA micronized particles and of the conventional jet-milled drug was used to compare, the results obtainable using the 2 techniques. Particularly, MMADs from 1.6 to 4.0 μm were obtained by SAA at the optimum operating conditions and by varying the concentration of the solution injected. MMAD of 6.0 μm was calculated for the jet-milled drug. SAA samples also exhibited narrower particle size distribution (PSD). A good control of particle size and distribution together with no drug degradation was obtained by SAA process.

Keywords: supercritical fluid, microparticles, carbon dioxide, asthma-controlling drug

Full Text

The Full Text of this article is available as a PDF (326K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Hickey AJ. Pharmaceutical Inhalation Aerosol Technology. New York, NY: Marcel Dekker Inc; 1996.
2. Matson DW, Fulton JL, Petersen RC, Smith RD. Expansion of supercritical fluid solution: solute formation of powders. Thin films and fibers. Ind Eng Chem Res. 1987;26:2298–2306. doi: 10.1021/ie00071a021. [Cross Ref]
3. Reverchon E, Della Porta G, Taddeo R. Solubility and micronization of griseofulvin in supercritical CHF3. Ind Eng Chem Res. 1995;34:4087–4091. doi: 10.1021/ie00038a051. [Cross Ref]
4. Sencar-Bozic P, Sreie S, Knez Z, Kere J. Improvement of nifedipine dissolution characteristics using supercritical CO2. Int J Pharm. 1997;148–2:123–130. doi: 10.1016/S0378-5173(96)04838-7. [Cross Ref]
5. Kere J, Srcic S, Knez Z, Sencar-Bozic P. Micronization of drugs using supercritical carbon dioxide. Int J Pharm. 1999;182:33–39. doi: 10.1016/S0378-5173(99)00063-0. [PubMed] [Cross Ref]
6. Bleich J, Kleinebudde P, Muller BW. Influence of gas density and pressure on microparticles produced with the ASES process. Int J Pharm. 1994;106:77–84. doi: 10.1016/0378-5173(94)90278-X. [Cross Ref]
7. Subramaniam MR, Rajewski RA, Snavely K. Pharmaceutical processing with supercritical carbon dioxide. J Pharm Sci. 1997;86–8:885–890. doi: 10.1021/js9700661. [PubMed] [Cross Ref]
8. Reverchon E, Della Porta G. Production of antibiotic micro- and nano-particles by supercritical antisolvent precipitation. Powder Technology. 1999;106:23–29. doi: 10.1016/S0032-5910(99)00062-5. [Cross Ref]
9. Rehman M, Shekunov BY, York P, et al. Optimisation of powders for pulmonary delivery using supercritical fluid technology. Eur J Pharm Sci. 2004;22:1–17. doi: 10.1016/j.ejps.2004.02.001. [PubMed] [Cross Ref]
10. Sievers RE, Milewski PD, Sellers DP, Kusek KD, Kleutz PG, Miles BA. Supercritical CO2-assisted methods for the production and pulmonary administration of pharmaceuticals aerosol. J Aerosol Sci. 1998;29–1:1271–1272. doi: 10.1016/S0021-8502(98)90818-7. [PubMed] [Cross Ref]
11. Sellers SP, Clark GS, Sievers RE, Carpenter JF. Dry powders of stable protein formulation from aqueous solutions prepared using supercritical CO2-assisted atomization. J Pharm Sci. 2001;90:785–797. doi: 10.1002/jps.1032. [PubMed] [Cross Ref]
12. Reverchon E. Supercritical assisted atomization to produce micro-and/or nanoparticles of controlled size and distribution. Ind Eng Chem Res. 2002;41:2405–2411. doi: 10.1021/ie010943k. [Cross Ref]
13. Reverchon E.Process for production of micro and/or nano particles. WO03004142. January 16, 2003.
14. Della Porta G., Reverchon E. Engineering Powder Properties by Supercritical Fluid for Optimum Drug Delivery. Part 2: Supercritical-Assisted Atomization. BioProcess Intl. 2005;3(3):54–60.
15. Reverchon E, Della Porta G. Micronization of some antibiotics by supercritical assisted atomization. J Supercrit Fluids. 2003;26–3:243–252. doi: 10.1016/S0896-8446(02)00162-6. [Cross Ref]
16. Reverchon E, Della Porta G. Terbutaline microparticles suitable for aerosol delivery produced by supercritical assisted atomization. Int J Pharm. 2003;258:1–9. doi: 10.1016/S0378-5173(03)00024-3. [PubMed] [Cross Ref]
17. Reverchon E, Della Porta G, Spada A, Antonacci A. Griseofulvin dissolution rate improvement by supercritical assisted atomization. J Pharm Pharmacol. 2004;56–11:1379–1387. doi: 10.1211/0022357044751. [PubMed] [Cross Ref]
18. Kane JM, Maynard GD, Burkholder T, et al. Substituted 4-(1H-benzimidazol-2-yl-amino) piperidines useful for the treatment of allergic diseases.US patent 6211199. April 3, 2001.
19. Carlo PF, Slowik JG, Worsnop DR, Davidovits P, Jimenez JL. Particle morphology and density characterization by combined mobility and aerodynamic diameter measurements. Part 1. Theory, Aerosol Science & Technology. 2004;38:1185–1205. doi: 10.1080/027868290903907. [Cross Ref]
20. Ohe S. Vapour-Liquid Equilibrium Data at High Pressure. Amsterdam, The Netherlands: Elsevier; 1990.
21. Rhodes M. Introduction to Particle Technology. New York, NY: John Wiley & Sons; 1999.
22. ICH Harmonized Tripartite Guideline for Residual Solvents, Step 4. International Conference on Harmonization; July 17, 1997.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists